Emergent Biosolutions lands $19M federal contract to produce Ebola drug - Technical.ly Baltimore

Business

Jul. 20, 2015 1:55 pm

Emergent Biosolutions lands $19M federal contract to produce Ebola drug

The drug, which is being compared to ZMapp, will be manufactured in East Baltimore.
Ebola virus budding from the surface of a Vero cell.

Ebola virus budding from the surface of a Vero cell.

(Photo via Wikimedia Commons)

A U.S. government agency awarded a $19.7 million contract to Emergent Biosolutions to develop a treatment for the Ebola virus.

Through the Biomedical Advanced Research and Development Authority (BARDA) contract, Emergent will manufacture an Ebola drug similar to the experimental ZMapp treatment that was used to treat American patients during last year’s Ebola outbreak in West Africa.

The drug will be manufactured at Emergent’s facility in East Baltimore.

In 2012, the company’s Bayview campus was designated as a Center for Innovation in Advanced Development and Manufacturing (CIADM) by the federal government, giving it increased potential to land such jobs. This contract is the first Ebola-related contract BARDA awarded under that public-private partnership model.

ZMapp, which was developed by manufacturing antibodies from tobacco plants, got attention after it was used on three American patients infected with Ebola in West Africa in 2014. With no vaccine for Ebola available, medical pros were seeking solutions that could be used in a hurry. Two of the U.S. patients who were given the drug ultimately survived. However, a Maryland surgeon who was given the treatment later died.

In the fall, the U.S. government announced plans to further study ZMapp. Emergent’s contract represents a step in that effort. Specifically, Emergent will develop and manufacture three monoclonal antibodies. Instead of ZMapp’s tobacco cells, however, the company’s scientists will use Chinese hamster ovary cells.

The Ebola outbreak has slowed down in West Africa, but the deadly virus is lingering.

According to the World Health Organization, 30 new cases were reported last week. BARDA’s efforts reflect an outpouring of U.S. government funding that came amid the outbreak as officials sought to develop a vaccine that would curb the disease, and prevent a public health crisis of that magnitude from happening again.

Advertisement

Earlier this year, Emergent made a separate booster for an Ebola vaccine that is undergoing trials in Europe.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Protenus cofounder Robert Lord is returning to JHU medical school, joining LionBird Ventures as partner

Chesapeake Digital Health Exchange aims to spur regional startup growth

Fearless, SmartLogic team up on Challenge.gov development

SPONSORED

Baltimore

Technology is ever evolving — shouldn’t business education be, too?

Annapolis Junction, MD

Asymmetrik

FULL-STACK DEVELOPER

Apply Now

Annapolis Junction, MD

Asymmetrik

SOFTWARE ENGINEER

Apply Now

Annapolis Junction, MD

Asymmetrik

FRONT-END DEVELOPER

Apply Now

This earmuff-style technology looks to make life less ruff for military working dogs

emocha and University of Maryland School of Pharmacy join forces on medication reviews

This apprenticeship is designed to bring gov contractor biz dev to smaller firms

SPONSORED

Baltimore

How independence fuels confidence and professional development at SmartLogic

Philadelphia, PA - Center City

Odessa

Sr. Project Manager – ERP Implementations

Apply Now

Philadelphia, PA - Center City

Odessa

Business Architect

Apply Now

Philadelphia, PA

Vistar Media

QA Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!